Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study
More than 10% of patients who received LMWH for cancer-associated VTE experienced VTE recurrence or bleeding. AC management options in this patient population should be prospectively assessed in clinical trials.
Authors
- Nadia Quignot (ORCID: https://orcid.org/0000-0001-8718-1307)
- Laurent Bertoletti (ORCID: https://orcid.org/0000-0001-8214-3010)
- Isabelle Mahé (ORCID: https://orcid.org/0000-0003-1760-7880)
- Artak Khachatryan (ORCID: https://orcid.org/0000-0003-3888-2347)
- Audrey Moniot
- Gaëlle Gusto
- Ruth Mokgokong (ORCID: https://orcid.org/0000-0002-6278-4969)
- José Chaves (ORCID: https://orcid.org/0000-0003-3820-3009)
- Sylvain Van Roy
- Lucas André
Institutions
- Saint Louis University (ES)
- Pfizer (United Kingdom) (GB)
- Université Paris Cité (FR)
- Pfizer (France) (FR)
- Pfizer (Spain) (ES)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1016/j.rpth.2024.102642
- Citations
- 2
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.10
Funders
- Bristol-Myers Squibb
- Pfizer
- Conservatoire National des Arts et Métiers